SEC Filing Summary: Qualigen Therapeutics, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Qualigen Therapeutics, Inc. (Note: The input metadata referenced "Aixcrypto," but the filing text explicitly identifies the registrant as Qualigen Therapeutics, Inc., trading under symbol QLGN). The report covers the quarterly period ended March 31, 2025. Qualigen is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, specifically the QN-302 program and a Pan-RAS program. The company also maintains a co-development agreement with Marizyme, Inc.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Expenses | $2,724,699 | $1,421,749 |
| Net Loss | $(2,646,172) | $(2,032,751) |
| Net Loss Per Share (Basic/Diluted) | $(1.82) | $(17.60) |
| Cash and Cash Equivalents (End of Period) | $30,210 | $93,217 |
| Net Cash Used in Operating Activities | $(1,589,396) | $(783,586) |
| Total Current Liabilities | $2,814,404 | $2,007,483 |
| Accumulated Deficit | $(125,707,745) | $(118,835,135) |
Material Changes vs. Prior Period
- General and Administrative (G&A) Expenses: Increased by 135% to $2.5 million, primarily driven by $1.4 million in investor relations expenses incurred to raise funding.
- Research and Development (R&D): Decreased by 90% to $33,167 due to the slowing of development programs (QN-302 and Pan-RAS) in Q2 2024 to conserve cash.
- Credit Loss Expense: A new expense of $197,000 was recorded for the allowance of credit losses on short-term notes receivable from Marizyme, Inc.
- Liquidity: Cash balances dropped significantly from $1.17 million at year-end 2024 to $30,210 at March 31, 2025.
- Debt: The company issued $750,000 in short-term promissory notes during the quarter, which are due within six months and carry a potential default penalty.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses, negative cash flows, and minimal cash on hand ($30k).
- Funding Strategy: The company borrowed $3.5 million from nine investors between January and June 2025 and plans to close a private placement equity transaction in July 2025 to fund operations through year-end.
- Legal Proceedings: The company is a defendant in a lawsuit filed by LifeSci Capital LLC alleging failure to pay $503,483 in placement agent fees. The company disputes the claim and is vigorously defending the action.
- Nasdaq Listing Status: The company received a delisting notice for failing to file its 2024 10-K on time. An appeal was granted, allowing continued listing contingent on filing the 2024 10-K by June 30, 2025, and this 10-Q by July 18, 2025.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing insufficient personnel, lack of segregation of duties, and inadequate IT general controls.
Key Facts for Investor Verification
- Critical Liquidity Risk: Verify the status of the planned July 2025 private placement; failure to raise capital could force immediate cessation of operations.
- Debt Obligations: Confirm the repayment terms and default penalties associated with the $3.5 million in short-term borrowings and the $843,615 in promissory notes outstanding.
- Marizyme Receivables: Assess the recoverability of the $2.2 million in short-term notes receivable from Marizyme, which already has a $557,000 allowance for credit losses.
- Legal Exposure: Monitor the discovery phase of the LifeSci Capital LLC lawsuit regarding the $503k alleged unpaid fees.
- Listing Compliance: Confirm the timely filing of the 2024 Annual Report (10-K) to maintain Nasdaq listing status.